Alnylam Pharmaceuticals, Inc.

Stocks

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-14 pm EDT			After hours 08:00:00 pm
281.26 ^USD	-2.36%		286.86	+1.99%

Jul. 14	Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says	MT
Jul. 14	BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating	MT

Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11

Published on 06/09/2026 at 01:05 pm EDT - Modified on 07/14/2026 at 01:06 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Salveen Richter (Analysts)

Great. Good morning. Thank you, everyone, for joining us. It's a pleasure to have with us the Alnylam team. With us is Jeff Poulton, CFO; and Pushkal Garg,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Alnylam Pharmaceuticals, Inc.

Jul. 14	Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says	MT
Jul. 14	BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating	MT
Jul. 09	Raymond James Adjusts Price Target on Alnylam Pharmaceuticals to $468 From $420, Maintains Outperform Rating	MT
Jul. 09	AstraZeneca's Wainua fails key heart disease trial, shares tumble	RE
Jun. 25	Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform	CI
Jun. 25	Alnylam Pharmaceuticals, Inc. - Special Call
Jun. 25	Alnylam Pharmaceuticals Expands Partnership With Komodo to Extend AI Platform Across Enterprise Functions	MT
Jun. 25	US prices for new drugs fell in 2025 as fewer costly gene therapies were launched	RE
Jun. 22	Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis	DJ
Jun. 10	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM
Jun. 03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
Jun. 03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT
Jun. 03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	CI
May. 27	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026	CI